AstraZeneca presents results from LAURA Phase III trial

Results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival for patients with unresectable, Stage III epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations, after chemoradiotherapy compared to placebo after CRT. These results were presented during the Plenary Session at the 2024 American Society of Clinical Oncology Annual Meeting and simultaneously published in The New England Journal of Medicine. Results showed TAGRISSO reduced the risk of disease progression or death by 84% compared to placebo as assessed by blinded independent central review. Median PFS was 39.1 months in patients treated with TAGRISSO versus 5.6 months for placebo. Importantly, a clinically meaningful PFS benefit was observed across all prespecified subgroups including sex, race, type of EGFR mutation, age, smoking history, and prior CRT. Overall survival data showed a favorable trend for TAGRISSO, although data were not mature at the time of this analysis. The trial will continue to assess OS as a secondary endpoint. Safety results and discontinuation rates due to adverse events were as expected and no new safety concerns were identified. Grade 3 or higher AEs from all causes occurred in 35% of patients in the TAGRISSO arm versus 12% in the placebo arm.